This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
CSNK2A1 / Casein kinase II subunit alpha · IHC design guide
Design Immunohistochemistry for CSNK2A1
Plan chromogenic paraffin IHC for CSNK2A1 around its nuclear and cytoplasmic tissue pattern (HPA tissue IHC). This guide covers fixation consistency, controls and scoring while flagging that staining may include protein from more than one gene (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
CSNK2A1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclear and cytoplasmic (HPA tissue IHC) | |
| Staining pattern | Nuclear and cytoplasmic staining in most tissues (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A02398-2) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | Adipose tissue |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific) | |
| Caveat | Staining may include protein from more than one gene (HPA tissue IHC) | |
| Regulation | Rises with gastric carcinoma progression (UniProt) | |
| Isoform / epitope | 2 isoforms; epitope differences are unspecified (UniProt) |
Section 1
Recommended CSNK2A1 IHC & IF Protocols
The catalog antibody protocol (datasheet A02398-2) is accompanied by three published CSNK2A1 IHC workflows and one report of HPA-derived IHC settings (PMC8303481; PMC6945564; PMC8487869; PMC7395738).
| Sample | Paraffin-embedded human stomach cancer tissue; fixative not specified (datasheet A02398-2) |
| Fixation | Image fixative and duration unreported (datasheet A02398-2); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A02398-2); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A02398-2) |
| Primary antibody | Rabbit anti-CSNK2A1, 1:50 recommended; image 2 μg/ml (datasheet A02398-2) |
| Primary incubation | Overnight at 4 °C (datasheet A02398-2) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet A02398-2) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | CSNK2A1-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: Nuclear and cytoplasmic expression in most tissues. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA pH 8.0 for the catalog antibody (datasheet A02398-2). The published settings were reported with other antibodies or samples (PMC8303481; PMC6945564; PMC8487869; PMC7395738).
Section 2
What Is the Expected CSNK2A1 Staining Pattern?
CSNK2A1 is a nuclear protein with no transmembrane segment (UniProt P68400: location and topology). In tissue IHC, expect nuclear and cytoplasmic staining in many cell types, including glandular cells, neurons and hematopoietic cells (HPA: tissue profile). HPA rates the tissue pattern Supported, with medium agreement between staining and RNA data, and cautions that staining may detect protein from more than one gene (HPA: reliability).
| Nuclear staining, with some cytoplasmic staining, in colon or duodenum glandular cells. | This fits the reported tissue pattern; both cell types have High staining (HPA: tissue IHC). Compare cells within the section before treating staining intensity as a quantitative measure of CSNK2A1 abundance. |
| Signal is confined to cell borders or extracellular material, with no convincing cellular staining. | That distribution does not fit the reported nuclear and cytoplasmic tissue pattern (HPA: tissue profile; UniProt P68400: nucleus, no transmembrane segment). Check whether the same distribution appears in a control lacking primary antibody (general IHC practice). |
| Adipocytes stain strongly while adjacent cells show little signal. | Adipocytes are reported as Not detected (HPA: adipose tissue). Consider nonspecific antibody binding or endogenous detection activity; one unexpected cell population alone cannot establish which mechanism is responsible (general IHC practice). |
| Weak, widespread chromogen obscures nuclei and tissue boundaries. | Interpret localisation only after background is controlled. Widespread haze can reflect excess primary antibody, inadequate blocking or residual detection activity (general IHC practice); it does not demonstrate the HPA nuclear and cytoplasmic pattern. |
| No signal in colon glandular cells while tissue and counterstain remain visible. | Colon glandular cells are reported High (HPA: colon). A blank result calls for a run control and a check of reagent activity, retrieval and detection steps (general IHC practice); it does not by itself establish absent CSNK2A1. |
💡Expected CSNK2A1 appearanceCall a section positive when identifiable cells show nuclear staining, with possible cytoplasmic staining, and a clear signal in a reported High population such as colon glandular cells; isolated strong adipocyte or cell-border staining is suspect (HPA: tissue IHC; UniProt P68400: nucleus and topology).
| Tissue and cell selection | HPA reports High staining in colon and duodenum glandular cells, cerebral cortex neurons and bone marrow hematopoietic cells; adipocytes are Not detected (HPA: tissue IHC). These are observed patterns, not guarantees for every section. |
| Normal stomach versus carcinoma | Normal stomach glandular cells are listed Low (HPA: stomach). CSNK2A1 expression is reported to rise with gastric carcinoma progression (UniProt P68400: tissue specificity); the two observations concern different tissue contexts. |
| Antibody identity and specificity | HPA lists IHC as Supported for HPA061698, CAB020680 and CAB069395, while providing no IHC status for HPA059206 (HPA: antibody validation). Its tissue summary cautions that staining may detect protein from more than one gene (HPA: reliability). |
| Nuclear versus cytoplasmic readout | UniProt lists the nucleus, while HPA tissue IHC describes nuclear and cytoplasmic expression (UniProt P68400: location; HPA: tissue profile). Score those compartments separately so cytoplasmic signal does not erase the nuclear readout. |
| IF/ICC cross-check | If using IF/ICC to examine localisation, expect mainly nucleoplasmic signal; HPA also lists primary cilium localisation as uncertain (HPA: subcellular ICC-IF). This cellular observation does not set an IHC staining threshold or an IF protocol. |
| Situation | Likely cause | Next action |
|---|---|---|
| Reported High control tissue is blank. | The run may have failed at retrieval, primary antibody incubation or detection (general IHC practice). | Inspect the run control and reagent steps, then repeat with a reported High cell population such as colon glandular cells (HPA: colon). Do not infer target absence from one blank section. |
| Only diffuse cytoplasmic colour is visible. | This is incomplete support for localisation because the tissue profile includes nuclear staining (HPA: tissue profile). | Assess nuclei and cytoplasm independently against the counterstain; review background and detection controls before scoring the section (general IHC practice). |
| Adipocytes appear strongly positive. | The result conflicts with the reported Not detected adipocyte pattern (HPA: adipose tissue); nonspecific binding or detection activity is possible (general IHC practice). | Compare a control lacking primary antibody and inspect nearby cells. Treat the adipocyte signal as unresolved unless its source can be distinguished (general IHC practice). |
| Colour covers most of the section, including spaces between cells. | High background can come from blocking, washing, antibody concentration or the detection system (general IHC practice). | Check a control lacking primary antibody and adjust the implicated workflow step; then reassess nuclear and cytoplasmic localisation (general IHC practice; HPA: tissue profile). |
| Stomach glandular cells stain weakly, despite a strong colon control. | That difference is compatible with Low staining in normal stomach and High staining in colon glandular cells (HPA: tissue IHC). | Record the cell type and tissue context before calling the run a failure. Apply the same scoring criteria across sections (general IHC practice). |
| A nuclear signal is seen, but CSNK2A1 specificity remains uncertain. | A matching location alone cannot resolve HPA's warning that staining may detect protein from more than one gene (HPA: reliability). | Document the antibody used and its HPA IHC status; compare staining with an independent specificity control where available (HPA: antibody validation; general IHC practice). |
Experiment evidence
IHC & IF images showing CSNK2A1 staining
A02398-2 · IHCIHC analysis of CSNK2A1 using anti-CSNK2A1 antibody (A02398-2). CSNK2A1 was detected in a paraffin-embedded section of human stomach cancer
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000101266-CSNK2A1/tissue/cerebral+cortex#imid_19073055
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000101266-CSNK2A1/tissue/colon#imid_19072981
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000101266-CSNK2A1/tissue/liver#imid_19072974
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000101266-CSNK2A1/tissue/kidney#imid_19072975
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody CAB020680; green = CSNK2A1, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody CAB020680; green = CSNK2A1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for CSNK2A1 IHC & IF
🧪Run adrenal gland first: its glandular cells should stain (HPA: High in adrenal gland glandular cells). Run adipose tissue as the negative comparator, where adipocytes are not detected (HPA: Not detected in adipocytes); no validated internal negative cell type is identified on the adrenal slide, so assess cells outside the glandular compartment against background without assuming they are target-negative (HPA: adrenal gland glandular cells).
Positive control tissue: Adrenal gland (Glandular cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show CSNK2A1 in A-431, U-251MG, Hep-G2, U2OS, KOLF2.1J, with annotated localisation: Nucleoplasm (supported) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control, a rabbit isotype control matched to the primary antibody’s clonality if known, and a CSNK2A1 knockout sample or validated peptide-block control for specificity (selected IHC caption: rabbit primary and anti-rabbit secondary). Quench endogenous peroxidase and assess background in the adrenal section before interpreting DAB staining (selected IHC caption: peroxidase detection with DAB; HPA: adrenal gland selected as positive tissue).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected A02398-2 paraffin-section caption does not state a fixative (selected IHC caption: fixative not stated). The reported IHC procedure uses heat retrieval in EDTA at pH 8.0, but the evidence does not establish whether retrieval is essential or whether frozen sections or IF would be easier (selected IHC caption: heat retrieval in EDTA; HPA: ICC-IF images available). No adrenal-specific artefact is reported in the supplied evidence; check the positive slide for endogenous peroxidase background (HPA: adrenal gland positive row; selected IHC caption: peroxidase detection with DAB).
HPA tissue IHC evidence for CSNK2A1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — Medium consistency between antibody staining and RNA expression data. Caution, targets protein from more than one gene.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Breast | Glandular cells | High | Protein (IHC) | HPA → |
| Cerebellum | Cells in molecular layer | High | Protein (IHC) | HPA → |
| Cerebral cortex | Neuronal cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced CSNK2A1 IHC Tips
Use the catalog antibody’s paraffin-section IHC conditions as a starting point, then assess compartment, cell identity, and controls before scoring CSNK2A1.
Which retrieval condition should I try first when CSNK2A1 staining is weak?
Start with heat-mediated retrieval in EDTA pH 8.0 for paraffin sections (datasheet A02398-2). The demonstrated stain used 2 μg/ml primary antibody overnight at 4°C, so reproduce those conditions before changing retrieval (datasheet A02398-2). If staining remains weak, test citrate pH 6.0 on an adjacent section as a standard IHC fallback, keeping detection and exposure identical. Compare signal in intact nuclei and cytoplasm against matched controls, since both compartments appear in tissue staining (HPA: nuclear and cytoplasmic expression in most tissues). Reject a hotter or longer retrieval condition if tissue damage or diffuse background obscures cell boundaries.
Can I infer an optimal fixation condition from the published tissue stain?
The selected image documents a paraffin-embedded stomach cancer section but does not identify its fixative (datasheet A02398-2). Target-specific fixation sensitivity is therefore unknown; neither the tissue staining profile nor CSNK2A1 topology establishes an optimal fixation condition. For a new specimen series, record fixative, time before fixation, and processing history, then keep them consistent across comparison groups as standard IHC practice. Use the documented EDTA pH 8.0 retrieval and 2 μg/ml primary concentration as starting conditions (datasheet A02398-2). If signal differs by processing batch, compare matched control sections before interpreting the difference as a change in CSNK2A1 abundance.
How should I evaluate nuclear and cytoplasmic CSNK2A1 staining?
Score nuclear and cytoplasmic staining separately, because tissue IHC shows both in most tissues (HPA: nuclear and cytoplasmic expression). Nuclear signal is consistent with the protein record and supported nucleoplasmic localisation (UniProt P68400: nucleus; HPA subcellular: nucleoplasm supported). Apply the same compartment definitions to every section, and use the counterstain to distinguish stained nuclei from adjacent cytoplasm. A mainly membranous rim should prompt review of background and antibody specificity, since CSNK2A1 has no transmembrane segment (UniProt P68400 topology). Record cell type as well as compartment; a dark region alone does not identify which cells carry the stain.
Could isoforms or epitope accessibility explain discordant IHC results?
CSNK2A1 has 2 listed isoforms, but the supplied antibody caption does not identify its epitope (UniProt P68400: isoforms 1 and 2; datasheet A02398-2). Its kinase domain spans residues 39–324, and several recorded phosphorylation sites lie near the C terminus (UniProt P68400: domains and modified residues). Those facts alone cannot establish whether fixation, retrieval, or phosphorylation changes this antibody’s binding. If sections disagree, first repeat the documented EDTA pH 8.0 retrieval and matched detection conditions (datasheet A02398-2). Then seek epitope mapping or an independently validated antibody before assigning a pattern to a particular isoform or modification.
How can I check an IHC pattern with a separate IF experiment?
Use IF as a separate validation experiment, while scoring this page’s paraffin-section result by chromogenic IHC (datasheet A02398-2: paraffin-section IHC). Multiplex CSNK2A1 with a validated marker for the cell population being assessed, choosing spectrally separated fluorophores and a far-red channel when tissue autofluorescence affects shorter wavelengths. Because CSNK2A1 lacks a transmembrane segment and has supported nucleoplasmic localisation, permeabilise cells or sections sufficiently to expose intracellular epitopes (UniProt P68400 topology; HPA subcellular: nucleoplasm supported). Include single-colour and no-primary controls to distinguish bleed-through and autofluorescence from signal. Compare compartment and cell identity across methods without assuming identical staining intensity.
What should I change when DAB staining is diffuse or widespread?
First compare a no-primary section with the test section to identify detection-system or tissue background before changing the primary antibody concentration. The documented IHC used 10% goat serum blocking, 2 μg/ml primary antibody overnight at 4°C, and DAB detection (datasheet A02398-2). Treat a peroxidase block as a general chromogenic IHC step and verify it with the no-primary control; the caption does not document that block. If background persists, check washing, antibody concentration, and development time one variable at a time. Judge improvement by clearer cellular boundaries and nuclear or cytoplasmic detail, rather than by overall darkness (HPA: nuclear and cytoplasmic expression).
What is a defensible way to quantify CSNK2A1 in paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define comparable viable regions and score nuclear and cytoplasmic staining separately, reflecting the reported tissue pattern (HPA: nuclear and cytoplasmic expression in most tissues). For cell-level reporting, record the percentage of positive cells and an H-score using a fixed intensity scale across all slides. If cell density matters, report positive cells per mm² alongside total eligible cells per mm², so changes in cellularity remain visible. Normalise comparisons to the same cell population, sampled area, staining batch, and control section. Keep thresholds and image acquisition settings fixed, and exclude necrotic regions and section edges before comparing groups.
How do I distinguish genuine CSNK2A1 staining from artefact?
Give greatest weight to staining within intact cells in the expected nuclear or cytoplasmic compartments (UniProt P68400: nucleus; HPA: nuclear and cytoplasmic expression). Check cell identity rather than assuming every brown area represents the target; the tissue profile varies by cell population (HPA tissue IHC: cell-specific staining levels). Edge-enhanced staining, necrotic debris, and signal reproduced in a no-primary section warrant review as standard chromogenic IHC artefacts. Investigate a sharp membranous outline because no transmembrane segment is recorded for CSNK2A1 (UniProt P68400 topology). Finally, interpret staining cautiously if specificity is unresolved: the HPA tissue assessment warns that its antibodies target protein from more than one gene (HPA: reliability description).
Boster reagents
Best CSNK2A1 / Casein kinase II subunit alpha IHC Antibodies
Both catalog antibodies have IHC images from paraffin-embedded human tissue (A02398-2 and M02398 IHC captions). A02398-2 also lists IF/ICC, but has no IF image (A02398-2 applications and IF images).
Real IHC data
Anti-CSNK2A1 Antibody
Cat # A02398-2
The A02398-2 card will render with IHC staining of a paraffin-embedded human stomach cancer section (A02398-2 IHC caption). M02398 has a separate IHC caption for paraffin-embedded human colon, but is not among the supplied cards to render (M02398 IHC caption; cards payload).
Which to pick: For tissue IHC, A02398-2 has the shown human stomach cancer section, while M02398 has the shown human colon section (each SKU’s IHC caption); neither caption reports the fixative (each SKU’s IHC caption). For IF/ICC, choose A02398-2 based on its listed applications, with no IF figure supplied (A02398-2 applications and IF images). For cross-species work, both list human, mouse, and rat reactivity; A02398-2 is polyclonal and M02398 is monoclonal clone BBC-3 (catalog reactivity, dilution_raw, and clone).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P68400 (CSK21_HUMAN, Casein kinase II subunit alpha).
- Human Protein Atlas. CSNK2A1 tissue IHC expression (reliability: Supported).
- Human Protein Atlas. CSNK2A1 subcellular location (ICC-IF): Mainly localized to the nucleoplasm. In addition localized to the primary cilium..
- Human Protein Atlas. CSNK2A1 antibody validation summary (4 antibodies).
- CK2α/CSNK2A1 Induces Resistance to Doxorubicin through SIRT6-Mediated Activation of the DNA Damage Repair Pathway. Cells 2021 — PMC8303481.
- Effects of Casein Kinase 2 Alpha 1 Gene Expression on Mice Liver Susceptible to Type 2 Diabetes Mellitus and Obesity. International journal of medical sciences 2020 — PMC6945564.
- An Integrative Pan-Cancer Analysis of the Prognostic and Immunological Role of Casein Kinase 2 Alpha Protein 1 (CSNK2A1) in Human Cancers: A Study Based on Bioinformatics and Immunohistochemical Analysis. International journal of general medicine 2021 — PMC8487869.
- Signatures of co-deregulated genes and their transcriptional regulators in colorectal cancer. NPJ systems biology and applications 2020 — PMC7395738.
- PubMed PMID:2752008 — UniProt-cited evidence.
- PubMed PMID:2174700 — UniProt-cited evidence.
- PubMed PMID:8420794 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for CSNK2A1 (Casein kinase II subunit alpha). Expected localisation Nuclear and cytoplasmic (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A02398-2). Validated IHC antibody: A02398-2 at 1:50 recommended; image 2 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human stomach cancer tissue; fixative not specified (datasheet A02398-2); 2. Fixation: Image fixative and duration unreported (datasheet A02398-2); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A02398-2); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A02398-2); 8. Primary antibody: Rabbit anti-CSNK2A1, 1:50 recommended; image 2 μg/ml (datasheet A02398-2); 9. Primary incubation: Overnight at 4 °C (datasheet A02398-2). Watch for: Fixation: Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific); Caveat: Staining may include protein from more than one gene (HPA tissue IHC); Isoform / epitope: 2 isoforms; epitope differences are unspecified (UniProt); Regulation: Rises with gastric carcinoma progression (UniProt). Evidence: UniProt P68400, HPA tissue IHC · Supported, HPA ICC-IF · Mainly localized to the nucleoplasm. In addition localized to the…, Datasheet A02398-2, PMC8303481, PMC6945564. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/CSNK2A1/immunohistochemistry-ihc-guide.